What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Oncology, Surgery, Ovarian cancer and Chemotherapy.
His research combines Gastroenterology and Internal medicine.
His studies in Oncology integrate themes in fields like Response Evaluation Criteria in Solid Tumors, Serous fluid, Gynecology, Carcinoma and Adenocarcinoma.
His Surgery study combines topics in areas such as Colorectal cancer, Quality of life and Urology.
Amit M. Oza has researched Ovarian cancer in several fields, including Bevacizumab, Progression-free survival and Olaparib.
His Randomized controlled trial research includes elements of Patient satisfaction and Physical therapy.
His most cited work include:
- A phase 3 trial of bevacizumab in ovarian cancer. (1288 citations)
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial (857 citations)
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial (857 citations)
What are the main themes of his work throughout his whole career to date?
Amit M. Oza focuses on Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Phases of clinical research.
His research in Internal medicine intersects with topics in Gastroenterology and Surgery.
The study incorporates disciplines such as Olaparib, PARP inhibitor, Placebo, Rucaparib and Endometrial cancer in addition to Oncology.
His study focuses on the intersection of Ovarian cancer and fields such as Adverse effect with connections in the field of Nausea.
His biological study spans a wide range of topics, including Stage, Clinical endpoint and Tolerability.
His Clinical trial research incorporates themes from Randomized controlled trial, Disease and Quality of life.
He most often published in these fields:
- Internal medicine (75.35%)
- Oncology (61.71%)
- Ovarian cancer (38.46%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (75.35%)
- Oncology (61.71%)
- Ovarian cancer (38.46%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Ovarian cancer, Chemotherapy and In patient.
His studies deal with areas such as Placebo, Rucaparib and Olaparib as well as Internal medicine.
Amit M. Oza interconnects Cancer, PARP inhibitor, Phases of clinical research, Epithelial ovarian cancer and Platinum sensitive in the investigation of issues within Oncology.
His Ovarian cancer research includes themes of Clinical endpoint, Clinical trial, Adverse effect and Serous fluid.
His Clinical trial research is multidisciplinary, relying on both Randomized controlled trial and Disease.
The various areas that Amit M. Oza examines in his Chemotherapy study include Adjuvant chemotherapy and Cohort.
Between 2017 and 2021, his most popular works were:
- Epithelial ovarian cancer: Evolution of management in the era of precision medicine (167 citations)
- Epithelial ovarian cancer: Evolution of management in the era of precision medicine (167 citations)
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (119 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Amit M. Oza mainly investigates Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Adverse effect.
Amit M. Oza works mostly in the field of Internal medicine, limiting it down to topics relating to Placebo and, in certain cases, Regimen and Progression-free survival, as a part of the same area of interest.
Amit M. Oza has included themes like Germline mutation, Maintenance therapy, Epithelial ovarian cancer and Olaparib in his Oncology study.
His study in Ovarian cancer is interdisciplinary in nature, drawing from both Bevacizumab, Tolerability, PARP inhibitor and Immunotherapy.
His Chemotherapy research integrates issues from Stage, Serous fluid and Fallopian tube.
The Adverse effect study combines topics in areas such as DNA repair, Phases of clinical research and Monoclonal.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
